Cargando…

ITS-NANO - Prioritising nanosafety research to develop a stakeholder driven intelligent testing strategy

BACKGROUND: To assess the risk of all nanomaterials (NMs) on a case-by-case basis is challenging in terms of financial, ethical and time resources. Instead a more intelligent approach to knowledge gain and risk assessment is required. METHODS: A framework of future research priorities was developed...

Descripción completa

Detalles Bibliográficos
Autores principales: Stone, Vicki, Pozzi-Mucelli, Stefano, Tran, Lang, Aschberger, Karin, Sabella, Stefania, Vogel, Ulla, Poland, Craig, Balharry, Dominique, Fernandes, Teresa, Gottardo, Stefania, Hankin, Steven, Hartl, Mark GJ, Hartmann, Nanna, Hristozov, Danial, Hund-Rinke, Kerstin, Johnston, Helinor, Marcomini, Antonio, Panzer, Oliver, Roncato, Davide, Saber, Anne T, Wallin, Håkan, Scott-Fordsmand, Janeck J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3931673/
https://www.ncbi.nlm.nih.gov/pubmed/24521051
http://dx.doi.org/10.1186/1743-8977-11-9
_version_ 1782304693075050496
author Stone, Vicki
Pozzi-Mucelli, Stefano
Tran, Lang
Aschberger, Karin
Sabella, Stefania
Vogel, Ulla
Poland, Craig
Balharry, Dominique
Fernandes, Teresa
Gottardo, Stefania
Hankin, Steven
Hartl, Mark GJ
Hartmann, Nanna
Hristozov, Danial
Hund-Rinke, Kerstin
Johnston, Helinor
Marcomini, Antonio
Panzer, Oliver
Roncato, Davide
Saber, Anne T
Wallin, Håkan
Scott-Fordsmand, Janeck J
author_facet Stone, Vicki
Pozzi-Mucelli, Stefano
Tran, Lang
Aschberger, Karin
Sabella, Stefania
Vogel, Ulla
Poland, Craig
Balharry, Dominique
Fernandes, Teresa
Gottardo, Stefania
Hankin, Steven
Hartl, Mark GJ
Hartmann, Nanna
Hristozov, Danial
Hund-Rinke, Kerstin
Johnston, Helinor
Marcomini, Antonio
Panzer, Oliver
Roncato, Davide
Saber, Anne T
Wallin, Håkan
Scott-Fordsmand, Janeck J
author_sort Stone, Vicki
collection PubMed
description BACKGROUND: To assess the risk of all nanomaterials (NMs) on a case-by-case basis is challenging in terms of financial, ethical and time resources. Instead a more intelligent approach to knowledge gain and risk assessment is required. METHODS: A framework of future research priorities was developed from the accorded opinion of experts covering all major stake holder groups (government, industry, academia, funders and NGOs). It recognises and stresses the major topics of physicochemical characterisation, exposure identification, hazard identification and modelling approaches as key components of the current and future risk assessment of NMs. RESULTS: The framework for future research has been developed from the opinions of over 80 stakeholders, that describes the research priorities for effective development of an intelligent testing strategy (ITS) to allow risk evaluation of NMs. In this context, an ITS is a process that allows the risks of NMs to be assessed accurately, effectively and efficiently, thereby reducing the need to test NMs on a case-by-case basis. For each of the major topics of physicochemical characterisation, exposure identification, hazard identification and modelling, key-priority research areas are described via a series of stepping stones, or hexagon diagrams structured into a time perspective. Importantly, this framework is flexible, allowing individual stakeholders to identify where their own activities and expertise are positioned within the prioritisation pathway and furthermore to identify how they can effectively contribute and structure their work accordingly. In other words, the prioritisation hexagon diagrams provide a tool that individual stakeholders can adapt to meet their own particular needs and to deliver an ITS for NMs risk assessment. Such an approach would, over time, reduce the need for testing by increasing the reliability and sophistication of in silico approaches. The manuscript includes an appraisal of how this framework relates to the current risk assessment approaches and how future risk assessment could adapt to accommodate these new approaches. A full report is available in electronic format (pdf) at http://www.nano.hw.ac.uk/research-projects/itsnano.html. CONCLUSION: ITS-NANO has delivered a detailed, stakeholder driven and flexible research prioritisation (or strategy) tool, which identifies specific research needs, suggests connections between areas, and frames this in a time-perspective.
format Online
Article
Text
id pubmed-3931673
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-39316732014-02-22 ITS-NANO - Prioritising nanosafety research to develop a stakeholder driven intelligent testing strategy Stone, Vicki Pozzi-Mucelli, Stefano Tran, Lang Aschberger, Karin Sabella, Stefania Vogel, Ulla Poland, Craig Balharry, Dominique Fernandes, Teresa Gottardo, Stefania Hankin, Steven Hartl, Mark GJ Hartmann, Nanna Hristozov, Danial Hund-Rinke, Kerstin Johnston, Helinor Marcomini, Antonio Panzer, Oliver Roncato, Davide Saber, Anne T Wallin, Håkan Scott-Fordsmand, Janeck J Part Fibre Toxicol Research BACKGROUND: To assess the risk of all nanomaterials (NMs) on a case-by-case basis is challenging in terms of financial, ethical and time resources. Instead a more intelligent approach to knowledge gain and risk assessment is required. METHODS: A framework of future research priorities was developed from the accorded opinion of experts covering all major stake holder groups (government, industry, academia, funders and NGOs). It recognises and stresses the major topics of physicochemical characterisation, exposure identification, hazard identification and modelling approaches as key components of the current and future risk assessment of NMs. RESULTS: The framework for future research has been developed from the opinions of over 80 stakeholders, that describes the research priorities for effective development of an intelligent testing strategy (ITS) to allow risk evaluation of NMs. In this context, an ITS is a process that allows the risks of NMs to be assessed accurately, effectively and efficiently, thereby reducing the need to test NMs on a case-by-case basis. For each of the major topics of physicochemical characterisation, exposure identification, hazard identification and modelling, key-priority research areas are described via a series of stepping stones, or hexagon diagrams structured into a time perspective. Importantly, this framework is flexible, allowing individual stakeholders to identify where their own activities and expertise are positioned within the prioritisation pathway and furthermore to identify how they can effectively contribute and structure their work accordingly. In other words, the prioritisation hexagon diagrams provide a tool that individual stakeholders can adapt to meet their own particular needs and to deliver an ITS for NMs risk assessment. Such an approach would, over time, reduce the need for testing by increasing the reliability and sophistication of in silico approaches. The manuscript includes an appraisal of how this framework relates to the current risk assessment approaches and how future risk assessment could adapt to accommodate these new approaches. A full report is available in electronic format (pdf) at http://www.nano.hw.ac.uk/research-projects/itsnano.html. CONCLUSION: ITS-NANO has delivered a detailed, stakeholder driven and flexible research prioritisation (or strategy) tool, which identifies specific research needs, suggests connections between areas, and frames this in a time-perspective. BioMed Central 2014-02-13 /pmc/articles/PMC3931673/ /pubmed/24521051 http://dx.doi.org/10.1186/1743-8977-11-9 Text en Copyright © 2014 Stone et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Stone, Vicki
Pozzi-Mucelli, Stefano
Tran, Lang
Aschberger, Karin
Sabella, Stefania
Vogel, Ulla
Poland, Craig
Balharry, Dominique
Fernandes, Teresa
Gottardo, Stefania
Hankin, Steven
Hartl, Mark GJ
Hartmann, Nanna
Hristozov, Danial
Hund-Rinke, Kerstin
Johnston, Helinor
Marcomini, Antonio
Panzer, Oliver
Roncato, Davide
Saber, Anne T
Wallin, Håkan
Scott-Fordsmand, Janeck J
ITS-NANO - Prioritising nanosafety research to develop a stakeholder driven intelligent testing strategy
title ITS-NANO - Prioritising nanosafety research to develop a stakeholder driven intelligent testing strategy
title_full ITS-NANO - Prioritising nanosafety research to develop a stakeholder driven intelligent testing strategy
title_fullStr ITS-NANO - Prioritising nanosafety research to develop a stakeholder driven intelligent testing strategy
title_full_unstemmed ITS-NANO - Prioritising nanosafety research to develop a stakeholder driven intelligent testing strategy
title_short ITS-NANO - Prioritising nanosafety research to develop a stakeholder driven intelligent testing strategy
title_sort its-nano - prioritising nanosafety research to develop a stakeholder driven intelligent testing strategy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3931673/
https://www.ncbi.nlm.nih.gov/pubmed/24521051
http://dx.doi.org/10.1186/1743-8977-11-9
work_keys_str_mv AT stonevicki itsnanoprioritisingnanosafetyresearchtodevelopastakeholderdrivenintelligenttestingstrategy
AT pozzimucellistefano itsnanoprioritisingnanosafetyresearchtodevelopastakeholderdrivenintelligenttestingstrategy
AT tranlang itsnanoprioritisingnanosafetyresearchtodevelopastakeholderdrivenintelligenttestingstrategy
AT aschbergerkarin itsnanoprioritisingnanosafetyresearchtodevelopastakeholderdrivenintelligenttestingstrategy
AT sabellastefania itsnanoprioritisingnanosafetyresearchtodevelopastakeholderdrivenintelligenttestingstrategy
AT vogelulla itsnanoprioritisingnanosafetyresearchtodevelopastakeholderdrivenintelligenttestingstrategy
AT polandcraig itsnanoprioritisingnanosafetyresearchtodevelopastakeholderdrivenintelligenttestingstrategy
AT balharrydominique itsnanoprioritisingnanosafetyresearchtodevelopastakeholderdrivenintelligenttestingstrategy
AT fernandesteresa itsnanoprioritisingnanosafetyresearchtodevelopastakeholderdrivenintelligenttestingstrategy
AT gottardostefania itsnanoprioritisingnanosafetyresearchtodevelopastakeholderdrivenintelligenttestingstrategy
AT hankinsteven itsnanoprioritisingnanosafetyresearchtodevelopastakeholderdrivenintelligenttestingstrategy
AT hartlmarkgj itsnanoprioritisingnanosafetyresearchtodevelopastakeholderdrivenintelligenttestingstrategy
AT hartmannnanna itsnanoprioritisingnanosafetyresearchtodevelopastakeholderdrivenintelligenttestingstrategy
AT hristozovdanial itsnanoprioritisingnanosafetyresearchtodevelopastakeholderdrivenintelligenttestingstrategy
AT hundrinkekerstin itsnanoprioritisingnanosafetyresearchtodevelopastakeholderdrivenintelligenttestingstrategy
AT johnstonhelinor itsnanoprioritisingnanosafetyresearchtodevelopastakeholderdrivenintelligenttestingstrategy
AT marcominiantonio itsnanoprioritisingnanosafetyresearchtodevelopastakeholderdrivenintelligenttestingstrategy
AT panzeroliver itsnanoprioritisingnanosafetyresearchtodevelopastakeholderdrivenintelligenttestingstrategy
AT roncatodavide itsnanoprioritisingnanosafetyresearchtodevelopastakeholderdrivenintelligenttestingstrategy
AT saberannet itsnanoprioritisingnanosafetyresearchtodevelopastakeholderdrivenintelligenttestingstrategy
AT wallinhakan itsnanoprioritisingnanosafetyresearchtodevelopastakeholderdrivenintelligenttestingstrategy
AT scottfordsmandjaneckj itsnanoprioritisingnanosafetyresearchtodevelopastakeholderdrivenintelligenttestingstrategy